

**PCT**WORLD INTELLECTUAL PROPE  
International Bu

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9604929A1

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 38/38, 35/20</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/04929</b> <b>(43) International Publication Date:</b> 22 February 1996 (22.02.96)
<b>(21) International Application Number:</b> PCT/SE94/00742 <b>(22) International Filing Date:</b> 16 August 1994 (16.08.94)  <b>(71)(72) Applicants and Inventors:</b> SABHARWAL, Hemant [IN/SE]; Björn Järnsidas Gränd 12, S-224 77 Lund (SE). SVANBORG, Catharina [SE/SE]; Arkivgatan 4, S-223 59 Lund (SE).  <b>(74) Agent:</b> INGER, Lars, Ulf, Bosson; Garvaregatan 12, S-262 63 Ängelholm (SE).		<b>(81) Designated States:</b> AU, BR, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RU, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ANTIBACTERIAL COMPOSITION CONTAINING MULTIMERIC ALPHA-LACTALBUMIN  <b>(57) Abstract</b>  The present invention relates to the use of a multimeric alpha-lactalbumin in the preparation of preparations to be used in therapeutic or prophylactic treatment and/or for diagnostic use for infections, preferably of the respiratory tract, caused by bacteria, in particular <i>S. pneumoniae</i> and/or <i>H. influenzae</i> .		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<b>AT</b>	Austria	<b>GB</b>	United Kingdom	<b>MR</b>	Mauritania
<b>AU</b>	Australia	<b>GE</b>	Georgia	<b>MW</b>	Malawi
<b>BB</b>	Barbados	<b>GN</b>	Guinea	<b>NE</b>	Niger
<b>BE</b>	Belgium	<b>GR</b>	Greece	<b>NL</b>	Netherlands
<b>BF</b>	Burkina Faso	<b>HU</b>	Hungary	<b>NO</b>	Norway
<b>BG</b>	Bulgaria	<b>IE</b>	Ireland	<b>NZ</b>	New Zealand
<b>BJ</b>	Benin	<b>IT</b>	Italy	<b>PL</b>	Poland
<b>BR</b>	Brazil	<b>JP</b>	Japan	<b>PT</b>	Portugal
<b>BY</b>	Belarus	<b>KE</b>	Kenya	<b>RO</b>	Romania
<b>CA</b>	Canada	<b>KG</b>	Kyrgyzstan	<b>RU</b>	Russian Federation
<b>CF</b>	Central African Republic	<b>KP</b>	Democratic People's Republic of Korea	<b>SD</b>	Sudan
<b>CG</b>	Congo	<b>KR</b>	Republic of Korea	<b>SE</b>	Sweden
<b>CH</b>	Switzerland	<b>KZ</b>	Kazakhstan	<b>SI</b>	Slovenia
<b>CI</b>	Côte d'Ivoire	<b>LI</b>	Liechtenstein	<b>SK</b>	Slovakia
<b>CM</b>	Cameroon	<b>LK</b>	Sri Lanka	<b>SN</b>	Senegal
<b>CN</b>	China	<b>LU</b>	Luxembourg	<b>TD</b>	Chad
<b>CS</b>	Czechoslovakia	<b>LV</b>	Larvia	<b>TG</b>	Togo
<b>CZ</b>	Czech Republic	<b>MC</b>	Monaco	<b>TJ</b>	Tajikistan
<b>DE</b>	Germany	<b>MD</b>	Republic of Moldova	<b>TT</b>	Trinidad and Tobago
<b>DK</b>	Denmark	<b>MG</b>	Madagascar	<b>UA</b>	Ukraine
<b>ES</b>	Spain	<b>ML</b>	Mali	<b>US</b>	United States of America
<b>FI</b>	Finland	<b>MN</b>	Mongolia	<b>UZ</b>	Uzbekistan
<b>FR</b>	France			<b>VN</b>	Viet Nam
<b>GA</b>	Gabon				

Antibacterial composition containing multimeric alpha-lactalbumin.

## DESCRIPTION

### Technical field

The present invention relates to a novel antibacterial protein  
5 and compositions, in the form of pharmaceutical compositions,  
human food compositions, and animal feedstuffs comprising said  
protein to be used in the therapeutic and/or prophylactic  
treatment of infections caused by bacteria, in particular  
10 Streptococcus pneumoniae and/or Haemophilus influenzae, as well  
as a method for diagnosing infections caused by said bacteria.

The object of the present invention is to obtain a protein and  
compositions containing said protein for prophylactic and/or  
therapeutic treatment of infections caused by bacteria, in par-  
15 ticular Streptococcus pneumoniae and Haemophilus influenzae in  
the upper airways, ear-nose-and-throat infections, but also in  
the lower airways, e.g., the lungs by preventing adhesion of  
and/or causing a bactericidal effect on these bacteria. A fur-  
ther object is to be able to diagnose infections caused by  
20 these bacteria.

### Background of the invention

Natural antimicrobial compounds exist in secreted form as well  
as in cells of immune and non-immune origin.

25

Human milk has been used as a source for the purification of  
such compounds. These previously known compounds include speci-  
fic antibodies to the micro-organism surface structure, casein,  
lysozyme, and oligosaccharides. The mechanism of action differs  
30 between the groups of antimicrobial molecules. Antibodies and  
receptor analogues prevent micro-organism adherence to mucosal  
surfaces. Lysozyme attacks the cell wall etc.

The term bacterial adherence denotes the binding of bacteria to  
35 mucosal surfaces. This mechanic association is a means for the  
organism to resist elimination by the body fluids, and to es-  
tablish a population at the site where relevant receptors are

expressed. In most cases where the mechanisms of attachment have been identified it is a specific process. The bacterial ligands, commonly called adhesins bind to host receptors. For Gram-negative bacteria, the adhesins are commonly associated with pili or fimbriae, rigid surface organelles that help bacteria to reach the appropriate receptor in the complex cell surface. The fimbriae function as lectins, i.e. they show specificity for receptor epitopes provided by the oligosaccharide sequences in host glyco-conjugates (13). For Gram-positive bacteria, on the other hand, the adhesins are not expressed as a surface organelle, but rather linked to cell wall components and lipoteichoic acids (21,22). The receptor epitopes for Gram positive bacteria may consist of oligosaccharide sequences but can also be provided by peptides e.g. in connective tissue proteins (10).

The functional consequences of adherence depend on the virulence of the bacterial strain, and on the form of the receptor. When cell-associated, the ligand receptor interaction facilitates colonization and tissue attack (8). When secreted the receptor molecule will occupy the adhesins, and competitively inhibit attachment to the corresponding cell-bound receptor. Human milk is a rich source of such competing soluble receptor molecules.

The ability of specific antibodies to inhibit attachment is well established. This was first demonstrated for Vibrio cholera and oral streptococci. The anti-adhesive antibodies may act in either of two ways:

- 1) Antibodies to the receptor binding sites of the adhesin competitively inhibit receptor interaction or
- 2) antibodies to bacterial surface molecules which are not directly involved in adherence may agglutinate the bacteria and thereby reduce the number of organisms available for binding.

In either of the above cases the anti-adhesive activity of the antibody is attributed to the specificity of the antigen-com-

binning site. Recently an alternative mechanism of interaction between secretory IgA and E. coli based on lectin-carbohydrate interactions was identified.

- 5 Human milk drastically inhibits the attachment of Streptococcus pneumoniae and Haemophilus influenzae to human nasopharyngeal epithelial cells. It contains antibodies to numerous surface antigens on these organisms, e.g., the phosphoryl choline and capsular polysaccharides of S. pneumoniae, the lipopolysaccharide and outer membrane proteins of H. influenzae. Accordingly,  
10 some of the anti-adhesive activity in milk resides in the immunoglobulin fraction.

- The remaining anti-adhesive activity in the non-immunoglobulin  
15 fraction of milk may be explained by two types of molecules: free oligosaccharides and glycoproteins in the casein fraction.


- Human milk is unique with regard to its content of complex carbohydrates. The free oligosaccharide fraction of milk is dominated by the lactoseries and with improving methods of isolation and characterization of carbohydrates more than 130 oligosaccharides containing up to 20 monosaccharides per molecule  
20 have been identified.

- 25 An anti-adhesive activity against S. pneumoniae in a low molecular weight fraction (<5 kDa) of milk was explained by the free oligosaccharides. In contrast there was no such effect against H. influenzae (15).

- 30 An anti-adhesive activity of high molecular weight components of milk was localized to the casein fraction. Human casein drastically reduced the adherence both of S. pneumoniae and H. influenzae (15). This effect was species specific.

- 35 Alpha-lactalbumin is a metalloprotein, which shows some degree of heterogeneity depending on Ca(II) saturation and/or glycosylation (1). Alpha-lactalbumin acts as a specifier protein in

the lactose synthase system. During lactation, alpha-lactalbumin is formed in the mammary gland and it alters the substrate specificity of the galactosyltransferase enzyme from N-acetyl glucosamine (GlcNAc) to glucose (Glc), enabling lactose synthesis to take place:



10

Multiple forms of bovine, pig, sheep and goat alpha-lactalbumin have been isolated and well characterized (2, 3). These multiple forms differ in a few amino residues or the number of disulphide bonds (4, 5) but are all active in the lactose synthase system. The physiological relevance or functions of these different forms of alpha-lactalbumin are not known. Alpha-lactalbumin has undergone a high rate of evolutionary change and it shows homology with lysozyme (1). These two proteins are thought to originate from the same ancestral protein. Whereas lysozyme is known as an anti-bacterial agent, alpha-lactalbumin has not yet been found to have anti-bacterial functions.

15  
20

#### Description of the present invention

The present invention describes the identification of a new anti-bacterial protein or group of proteins from milk. The protein comprises a multimeric form of alpha-lactalbumin.

25

In the following this protein, or group of proteins, is abbreviated ALLP, Anti-adhesive Lactalbumin Like Protein.

30

The term antimicrobial or anti-bacterial protein used in the context of the present invention means here and in the following a protein which inhibits adherence of micro-organisms to tissue and/or exerts a bactericidal effect on microorganisms.

35

Further characteristics of the invention will be evident from the accompanying claims.

The present invention will be described more in detail with reference to the example given below.

#### EXPERIMENTAL

- 5 Purification of the active anti-adhesive and bactericidal protein (ALLP)

Milk samples from lactating women were screened for anti-adhesive activity against S. pneumoniae and H. influenzae. About 50 l of breast milk with high anti-adhesive activity was collected from one healthy donor and used for the purification of ALLP. About 5 l of milk was thawed at a time and centrifuged to remove fat. Casein was prepared from the defatted milk by acid precipitation at pH 4.6. ALLP was purified as outlined below:

- 15 (i) Ion-exchange chromatography of casein.

Casein was fractionated using an ion-exchange column (14 cm x 1.5 cm) packed with DEAE-Tris-acryl M (LKB, Sweden) attached to an FPLC (Pharmacia, Sweden) using a NaCl gradient: 100 mg of the lyophilized casein was dissolved in 10 ml of 0.01 M Tris-HCl, pH 8.5. After centrifugation, the sample was directly applied to the column and the run was under the following conditions: buffer A: 0.01 M Tris-HCl, pH 8.5; Buffer B: buffer A containing 1 M NaCl/l. Gradient program: from 0-3 ml 100% A, from 3-60 ml 15% B; from 60-85 ml 25% B; from 85-87 ml 100% B; from 87-89 ml 100% B for 2 min; from 89-120 ml 100% A. The gradient was not linear, but was interrupted at the elution of each peak for better separation. Flow rate: 1 ml/min, recorder 0.2 cm/min. The buffers were degassed and filtered through a 0.22  $\mu$ m filter before use. The peaks were monitored at 280 nm and the fraction size was 3 ml. Fractions were pooled as shown (FIG. 1A). The pools (I-VI) were then desalted by dialysis (membrane cut off 3.5 kD) against distilled water for at least 48 hrs, lyophilized and tested for anti-adhesive activity.

- 35 (ii) Gel chromatography of pool VI

100 mg of the active pool VI obtained after repeated FPLC fractionations of casein, were dissolved in 7 ml 0.06 M sodium

phosphate buffer, pH 7.0 and applied to a Sephadex<sup>R</sup> G-50 (Pharmacia, Sweden) column (93 cm x 2.5 cm). Flow rate was 30 ml/hr, peaks were monitored at 280 nm, 3 ml fractions were collected and pooled as shown (FIG. 2A). The pools were desalted by dialysis, lyophilized, tested for composition and for anti-adhesive activity.

Ion-exchange chromatography of commercial alpha-lactalbumin. 20 mg of commercial (Sigma) human or bovine alpha-lactalbumin were dissolved in 2 ml 0.01 M Tris-HCl, pH 8.5. The ion-exchange chromatography of alpha-lactalbumin was under similar conditions as described above for the fractionation of casein. The NaCl gradient was linear (not interrupted), flow rate was 1 ml/min, 3 ml fractions were collected and pooled as shown in FIG. 1B. The pools were dialysed, (membrane cut-off 3.5 kD), lyophilized, resuspended to the required concentration and tested for anti-adhesive activity.

Gel chromatography of commercial alpha-lactalbumin. Approximately 8-10 mg of commercial human or bovine alpha-lactalbumin (Sigma) were dissolved in 3 ml 0.06 M sodium phosphate buffer, pH 7.0 and fractionated on the Sephadex<sup>R</sup> G-50 column as described above. Flow rate was 30 ml/hr, peaks were monitored at 280 nm, 3 ml fractions were collected and pooled as shown (FIG. 2B). The pools were desalted by dialysis (membrane cut-off 3.5 kD) against distilled water for at least 48 hrs, lyophilized, tested for composition and for anti-adhesive activity. 6-8 mg retained of the material retained and eluting after 1 M NaCl during ion-exchange chromatography of alpha-lactalbumin were dissolved in 5 ml 0.06 M sodium phosphate buffer pH 7.0 and subjected to gel chromatography on the G-50 column as described above. 3 ml fractions were collected and pooled (FIG. 3). The pools were desalted, lyophilized, and tested for anti-adhesive activity.

35

Polyacrylamide gradient gel electrophoresis (PAGGE).

Analytical PAGGE was performed using 4-20% polyacrylamide pre-



cast gels (Bio-Rad, Richmond, CA) on a Bio-Rad Mini Protean II cell. To 10  $\mu$ l (5-10 mg/ml) each of the lyophilized fractions, an equal volume of sample buffer (13.1% 0.5 M Tris-HCl, pH 6.8, 10.5% glycerol, 1.2% SDS and 0.05% bromophenol blue) was added. 5 20  $\mu$ l of each was then loaded on to the gel which was run in Tris-glycine buffer (pH 8.3) with 0.1% SDS at 200V constant voltage for about 40 min. Staining of the proteins was made by immersing the gel in Coomassie Blue solution (0.1% in 40% methanol, 10% acetic acid) for about 0.5 hr. Destaining was by several 10 changes in 40% methanol, 10% acetic acid until a clear background was obtained.

#### Ion desorption mass spectrometry

ALLP and commercial alpha-lactalbumin were analyzed by ion- 15 desorption mass spectrometry.

#### Bacteria

S. pneumoniae (CCUG3114 and 10175) and H. influenzae (Hi198) were used throughout the experiments. These strains were known to 20 adhere well to human nasopharyngeal epithelial cells in vitro. These strains were initially isolated from the nasopharynx of children with frequent episodes of acute otitis media. The strains were kept lyophilized and were transferred to blood agar (10175) or Levinthal medium agar plates (Hi 198). S. pneu- 25 moniae was cultured for 9 hrs at 37°C in liquid medium (17), harvested by centrifugation and suspended in 1 ml of 0.9% NaCl with 1% choline. H. influenzae Hi198 was cultured for 4 hrs in haemophilus medium (18), harvested by centrifugation and suspended in phosphate-buffer saline, (PBS).

30

#### Adhesion inhibition

Adhesion and inhibition of adhesion was tested as previously described (15, 19). In brief, epithelial cells from the oropharynx of healthy donors ( $10^5$ /ml) were mixed with the bacterial 35 suspensions ( $10^9$ /ml). After incubation of bacteria and epithelial cells, unbound bacteria were eliminated by repeated cycles of centrifugation and resuspension in NaCl with 1% cho-

line (10175) or PBS (Hi 198).

The inhibitory activity of the different fractions was tested by preincubation with bacteria for 30 min at 37°C prior to addition of epithelial cells. The number of epithelial cells attached was counted with the aid of an interference contrast microscope (Ortolux II microscope with interference contrast equipment TE Leitz, Wetzlar). Adherence was given as the mean number of bacteria/cell for 40 epithelial cells. Inhibition was given in per cent of the value of the buffer control.

## RESULTS

### Properties of ALLP

ALLP was purified from human milk by fractionation of casein by ion-exchange chromatography and fractionation of the pool eluting after 1 M NaCl by gel chromatography. The ion-exchange fractionation profile of casein is shown in FIG 1A. Eluted fractions were pooled as indicated and tested for anti-adhesive activity. Pool VI retained the anti-adhesive activity of casein; this pool inhibited the attachment of S. pneumoniae and H. influenzae by more than 80% of the control (Table 3). The remaining fractions were inactive and were not analyzed further.

Pool VI was fractionated by gel chromatography on the Sephadex<sup>R</sup> G-50 column. The fractionation profile showed two distinct well separated peaks (FIG. 2A). Eluted fractions were pooled as shown, desalted, and tested for anti-adhesive activity. Pool K retained 98% of the anti-adhesive activity against S. pneumoniae and 91% of the activity against H. influenzae. Pool L was inactive (Table 3).

Analytical PAGGE of pool K showed the presence of bands in the 14-15 kD region, one band in the 30 kD region, and two bands stained in the 100 kD region. Pool L showed the presence of only one band in the 14-15 kD region (FIG. 2A, inset). The N-terminal amino acid sequence analysis showed that the bands of

pool K were similar and were identical to the N-terminal sequence of human alpha-lactalbumin. The active anti-adhesive protein in pool K was designated as Anti-adhesive Lactalbumin Like Protein (ALLP). ALLP reduced attachment of both S. pneumoniae and H. influenzae by about 60% at a concentration of 1 mg/ml.

#### Mass spectrometry of ALLP

The results from analytical PAGE suggested that ALLP might occur in a multimeric form. By ion laser desorption mass spectrometry, ALLP showed three distinct mass fragments (1, 2 and 3) at 14128.7 m/z, 28470.5 m/z and 42787.8 m/z, respectively (FIG. 4). These fragments agreed with the monomeric (14 m/z), dimeric (28 m/z) and trimeric (42 m/z) mass ranges of the protein.

#### Comparison of ALLP and commercial alpha-lactalbumin

When tested for anti-adhesive activity, commercial alpha-lactalbumin did not inhibit the adherence of S. pneumoniae or H. influenzae even at a concentration of 10 mg/ml (Table 4). ALLP showed stained bands in the 14-15 kD, 30 kD and the 100 kD regions, whereas the commercial alpha-lactalbumin stained only one band in the 14-15 kD region. The N-terminal amino acid sequence of ALLP showed complete homology with the sequence of human alpha-lactalbumin.

The lack of anti-adhesive activity of commercial alpha-lactalbumin, as compared to ALLP, might be due to a difference in their molecular forms. Therefore commercial human alpha-lactalbumin was subjected to ion laser desorption mass spectrometry. The spectrum showed only one mass fragment at 14128.7 m/z corresponding to the monomeric form of alpha-lactalbumin (calculated molecular mass = 14.079 kD). Thus commercial human alpha-lactalbumin was in the monomeric form and lacked anti-adhesive activity, whereas, ALLP was found to be multimeric and inhibited the attachment of S. pneumoniae and H. influenzae to human oropharyngeal cells in vitro.

### Ion-exchange chromatography of human alpha-lactalbumin

In order to test the effect of ion exchange chromatography on the anti-adhesive effect of commercial human alpha-lactalbumin, 20 mg of the commercial sample was applied onto the Tris-acryl column. The ion-exchange profile is shown in FIG. 1B. About 50% of the material applied was retained on the column and eluted after the application of 1 M NaCl (arrow, FIG. 1B). The different fractions were pooled as shown. After desalting and lyophilization the fractions were reconstituted to a concentration of about 5-10 mg/ml and tested for anti-adhesive activity.

### Anti-adhesive effect of human alpha-lactalbumin after ion-exchange chromatography

Before ion-exchange chromatography commercial human alpha-lactalbumin lacked anti-adhesive activity (Table 4). After it was subjected to ion-exchange chromatography, the pool which was retained and eluted with 1 M NaCl (pool LA<sub>2</sub>, FIG. 1B) inhibited the attachment of both S. pneumoniae and H. influenzae by more than 95% of the value of the control (Table 4). The other pool (LA<sub>1</sub>) obtained was inactive.

### Gel chromatography of human alpha-lactalbumin before and after ion-exchange chromatography

Since about 50% of the commercial human alpha-lactalbumin had become active after ion-exchange chromatography it was decided to check the mobility of the alpha-lactalbumin and pool LA<sub>2</sub> on gel chromatography.

The G-50 gel chromatographic profile of human alpha-lactalbumin before ion-exchange chromatography is shown in FIG. 2B. The alpha-lactalbumin eluted as a single peak, which gave a single band (14-15 kD) on PAGGE analysis (inset, FIG. 2B). This pool LA was found to be inactive when tested for anti-adhesive activity (Table 4).

The gel chromatographic profile of the active pool LA<sub>2</sub>, obtained after ion-exchange chromatography of alpha-lactalbumin is

shown in FIG. 3. This pool eluted as two well separated peaks (1 and 2, FIG. 3) corresponding to the eluting volumes of peaks K and L of the casein (FIG. 2A). When tested for anti-adhesive activity pool 1 retained the activity against both S. pneumo-  
5 niae and H. influenzae, whereas pool 2 was inactive (Table 4).

When pool 1 was analysed by analytical PAGGE a pattern similar to that of ALLP was obtained. bands stained at 14-15 kD region, 30 kD region, and two bands at 100 kD region. Pool 2 gave a  
10 single band at the 14-15 kD region, corresponding to monomeric alpha-lactalbumin (inset, FIG. 3).

Properties of commercial bovine alpha-lactalbumin.  
Since commercial human alpha-lactalbumin could be converted to  
15 the active multimeric form by ion-exchange chromatography it was decided to test the activity of bovine alpha-lactalbumin and to test its mobility on ion-exchange and gel chromatography. When tested for anti-adhesive activity, bovine alpha-lactalbumin was found to be inactive in inhibiting the attachment  
20 of S. pneumoniae and H. influenzae (Table 5).

20 mg of bovine alpha-lactalbumin were subjected to ion-exchange chromatography under similar conditions described above for human alpha-lactalbumin. 50% of the material applied to the  
25 column was retained and eluted after 1 M NaCl. The elution pattern was similar to that obtained for human alpha-lactalbumin (FIG. 1B). Pool BL<sub>2</sub> of bovine alpha-lactalbumin, corresponding to the elution volume of pool LA<sub>2</sub> of human alpha-lactalbumin (FIG. 1B) inhibited the attachment of S. pneumoniae by more  
30 than 95% and of H. influenzae by more than 80% of the value of the control (Table 5).

When subjected to gel chromatography on the G-50 column as described above, bovine alpha-lactalbumin eluted as a single peak  
35 corresponding to the elution volume of human alpha-lactalbumin (FIG. 2B). In contrast, the material in pool BL<sub>2</sub> resolved into two distinct peaks corresponding to pools 1 and 2 obtained for

human alpha-lactalbumin (FIG. 3). The pool eluting just after the void volume of the column (corresponding to pool 1) retained the anti-adhesive activity, whereas, the other pool was inactive. The active pool had a PAGGE pattern similar to that of ALLP, whereas, the inactive pool stained only one band in the 14-15 kD region.

Thus a portion of the commercial bovine alpha-lactalbumin was also converted to the active multimeric form by ion-exchange chromatography.

#### Bactericidal effect

The present ALLP was tested with regard to bactericidal effect on different strains of S. pneumoniae being known to be resistant to antibiotics, and some other strains of Streptococcus, E. coli, H. influenzae and M. cath.

Thereby the different bacterial strains were inoculated onto growth plates after incubation with ALLP in different concentrations. The viable counts (CFU) were determined at inoculation, 0.5 h, 2 h, and 4 h (hours), respectively, after inoculation. Table 1 below shows the viable counts after incubation to a medium containing 10 mg/ml of ALLP compared with the control.

Table 1

Viable counts (CFU) on S. pneumoniae strains after exposure to ALLP.

Strain designation	Viable counts (CFU)			
	0h	0.5h	2h	4h
10175 control	$2 \times 10^6$	$1 \times 10^6$	$1 \times 10^5$	$1 \times 10^4$
ALLP	$2 \times 10^5$	-	-	-
15006-92 control	$1 \times 10^4$	$2 \times 10^4$	$1 \times 10^3$	-
ALLP	$2 \times 10^4$	-	-	-

Table 1 cont'd

Strain			Viable counts (CFU)			
designation			0h	0.5h	2h	4h
5	14060-92	control	$2 \times 10^6$	$1 \times 10^5$	$1 \times 10^4$	-
		ALLP	$2 \times 10^5$	-	-	-
	15256-92	control	$1 \times 10^6$	$2 \times 10^6$	$2 \times 10^5$	$4 \times 10^4$
		ALLP	$2 \times 10^6$	-	-	-
10	14326-92	control	$4 \times 10^5$	$2 \times 10^5$	$2 \times 10^4$	$2 \times 10^3$
		ALLP	$7 \times 10^4$	-	-	-
	Prag 1828	control	$5 \times 10^6$	$2 \times 10^6$	$5 \times 10^5$	-
		ALLP	$5 \times 10^6$	-	-	-
	14091-92	control	$3 \times 10^5$	$5 \times 10^5$	$1 \times 10^5$	-
		ALLP	$7 \times 10^5$	-	-	-
15	14117-92	control	$2 \times 10^6$	$2 \times 10^6$	$2 \times 10^6$	-
		ALLP	$2 \times 10^6$	-	-	-
	14612-92	control	$3 \times 10^5$	$1 \times 10^5$	$2 \times 10^4$	$1 \times 10^3$
		ALLP	$3 \times 10^4$	-	-	-
	Dk 84/87	control	$1 \times 10^7$	$5 \times 10^6$	$2 \times 10^6$	$6 \times 10^4$
		ALLP	$3 \times 10^5$	-	-	-
20	14007-92	control	$1 \times 10^5$	$5 \times 10^4$	$4 \times 10^3$	-
		ALLP	$1 \times 10^5$	-	-	-
	14030-92	control	$5 \times 10^6$	$2 \times 10^6$	$2 \times 10^5$	-
		ALLP	$5 \times 10^6$	$2 \times 10^1$	-	-
25	14423-92	control	$6 \times 10^5$	$6 \times 10^6$	$1 \times 10^6$	$6 \times 10^5$
		ALLP	$2 \times 10^5$	$3 \times 10^1$	-	-
	4502- 93	control	$4 \times 10^5$	-	-	-
		ALLP	$5 \times 10^4$	-	-	-
	SA44165	control	$2 \times 10^5$	$5 \times 10^3$	-	-
		ALLP	$3 \times 10^5$	-	-	-
30	1017-92	control	$1 \times 10^6$	$5 \times 10^5$	$4 \times 10^3$	-
		ALLP	$9 \times 10^5$	-	-	-
	317-93	control	$4 \times 10^4$	$1 \times 10^4$	$5 \times 10^3$	-
		ALLP	$2 \times 10^3$	-	-	-
35	760-92	control	$2 \times 10^7$	$2 \times 10^6$	$1 \times 10^4$	$1 \times 10^4$
		ALLP	$8 \times 10^6$	-	-	-

Table 1 cont'd

Strain designation			Viable counts (CFU)			
			0h	0.5h	2h	4h
5	Hun 859	control	$6 \times 10^5$	$3 \times 10^5$	$2 \times 10^5$	$2 \times 10^5$
		ALLP	$3 \times 10^5$	-	-	-
	Hun 963	control	$1 \times 10^7$	$4 \times 10^6$	$1 \times 10^5$	-
		ALLP	$5 \times 10^6$	-	-	-
10	BN 241	control	$4 \times 10^6$	$5 \times 10^4$	$2 \times 10^4$	-
		ALLP	$2 \times 10^5$	-	-	-

Table 2

Viable counts (CFU) on different bacterial species

Strain designation			Viable counts (CFU)			
			0h	0.5h	2h	4h
15	<u>S. mitis</u>	control	$1 \times 10^6$	$10 \times 10^6$	$2 \times 10^5$	$1 \times 10^5$
	116	ALLP	$1 \times 10^6$	-	-	-
20	<u>S. sanguis</u>	control	$5 \times 10^7$	$3 \times 10^7$	$4 \times 10^7$	$5 \times 10^6$
	197	ALLP	$3 \times 10^7$	$2 \times 10^5$	$2 \times 10^2$	-
	<u>E. coli</u>	control	$6 \times 10^6$	$5 \times 10^6$	$3 \times 10^6$	$3 \times 10^6$
	60	ALLP	$7 \times 10^6$	$5 \times 10^6$	$1 \times 10^7$	$2 \times 10^7$
25		control	$5 \times 10^6$	$5 \times 10^6$	$5 \times 10^6$	$7 \times 10^6$
		ALLP	$5 \times 10^6$	$6 \times 10^6$	$1 \times 10^7$	$2 \times 10^7$
	<u>H. influenzae</u>	control	$4 \times 10^7$	$1 \times 10^7$	$4 \times 10^6$	$2 \times 10^5$
	21594	ALLP	$3 \times 10^7$	$4 \times 10^5$	$< 1 \times 10^3$	$< 1 \times 10^3$
30	21300	control	$4 \times 10^7$	$2 \times 10^7$	$5 \times 10^6$	$3 \times 10^5$
		ALLP	$4 \times 10^7$	$2 \times 10^6$	$2 \times 10^4$	$2 \times 10^3$
	<u>M. cath.</u>	control	$4 \times 10^5$	$3 \times 10^5$	$5 \times 10^4$	$2 \times 10^4$
	71257 C+	ALLP	$3 \times 10^5$	$2 \times 10^5$	$3 \times 10^3$	-
	71295 C+	control	$2 \times 10^7$	$1 \times 10^7$	$3 \times 10^6$	$6 \times 10^5$
		ALLP	$2 \times 10^7$	$5 \times 10^6$	$2 \times 10^6$	$3 \times 10^5$

C+ = beta-lactamase producing

A dose response curve was made up based on the bactericidal effect on S. pneumoniae 10175 at different levels of administration of ALLP compared with control (no addition). Thereby ALLP was administered at 0.1 mg/ml, 0.5 mg/ml, and 1.0 mg/ml,



respectively. The graph obtained is shown in FIG. 5. As evident therefrom as little as 0.1 mg/ml of ALLP provides a bactericidal effect on S. pneumoniae.

5 The viable counts were further determined using different control proteins, viz. bovine serum albumine (BSA), alphalactalbumine (bovine origin), lactoferrin (bovine origin) in a concentration of 10 mg/ml, and control (no protein). As evident from FIG. 6 these proteins had no bactericidal effect on S.  
10 pneumoniae 10175.

A new form of alpha-lactalbumin (ALLP) with anti-adhesive activity and bactericidal effect against the respiratory tract pathogens S. pneumoniae and H. influenzae was thus isolated  
15 and characterized from a human milk sample. Commercial human or bovine alpha-lactalbumin lacked anti-adhesive activity in the assay system. A portion of the commercial human and bovine alpha-lactalbumin was converted to active form by ion exchange chromatography. The active and non-active forms of alpha-  
20 lactalbumin showed different mobilities on gel chromatography and their staining patterns on gel electrophoresis were also different. By ion-desorption mass spectrometry analysis, ALLP was found to be in the trimeric form, whereas commercial alpha-lactalbumin was monomeric. The activated forms of commercial  
25 human and bovine alpha-lactalbumin showed gel pattern similar to the trimeric form. A portion of the monomeric form of alpha-lactalbumin was separated from the multimeric form and was found to be inactive in inhibiting the adherence of both S.  
pneumoniae and H. influenzae. The three forms of alpha-lact-  
30 albumin (mono, di and tri) existed in some sort of equilibrium after ion-exchange chromatography and could not successfully be separated from each other. This proposes that the active anti-adhesive alpha-lactalbumin (ALLP) is a multimeric form not previously identified in human milk.

35

The identification of ALLP in a previous casein preparation was a result of its purification being monitored by the biological

activity (16). It retained all of the anti-adhesive activity of casein and thus could be followed during the purification procedures. This form of alpha-lactalbumin has not previously been disclosed to be present in human milk. The early studies of the present inventors showed that the anti-adhesive effect of human milk against S. pneumoniae and H. influenzae was independent from the specific antibody activity and was concentrated in a casein fraction (15). Casein was, however, found to have both a bactericidal effect and an anti-adhesive effect. A bactericidal effect was present and was found to be more pronounced against S. pneumoniae than H. influenzae. The anti-adhesive activity remained intact after removal of the fatty acids from casein. The mechanism of adhesion inhibition of ALLP was found to be independent from its carbohydrate content. Carbohydrate analysis of ALLP showed the presence of only one monosaccharide unit associated with the molecule. Removal of this monosaccharide unit by glucosidase treatment did not alter the anti-adhesive effect of ALLP. Also since the commercial forms of human and bovine alpha-lactalbumin could be activated by ion-exchange chromatography, it is very unlikely that the carbohydrate play any role in the anti-adhesive or bactericidal effect of ALLP tested by the biological analysis system.

Being predominantly a whey protein, alpha-lactalbumin is usually purified from the alpha-lactalbumin rich fractions of whey. Since the monomeric form and the multimeric forms have different mobilities on gel chromatography, the active multimeric forms are lost during the purification procedures. It is thus not surprising that the commercial preparations of alpha-lactalbumin lacked anti-adhesive properties in the present system. Genetic variants of alpha-lactalbumin have been isolated from milk of other mammals including bovine. Most of these forms consist of four disulphide bonds and a form of bovine alpha-lactalbumin with three disulphide bonds have also been isolated (5). The physiological role of these different forms of alpha-lactalbumin is not known. The present data demonstrate that the monomeric alpha-lactalbumin completely lacked biologi-

cal activity in the present system. Aggregation and polymerization may therefore be an important event in the anti-adhesive activity of ALLP against S. pneumoniae and H. influenzae.

5 The present data demonstrate that the multimeric alpha-lactalbumin is active in adhesion inhibition of the respiratory tract pathogens and can thus play a role in the protection against respiratory and gastro-intestinal infections. It is also active as a bactericide on at least S. pneumoniae, even  
10 those being resistant to antibiotics.

#### COMMENTS

S. pneumoniae and H. influenzae are important causes of morbidity and mortality in all age groups. Respiratory tract infections, e.g., meningitis, otitis, and sinusitis are caused by  
15 bacteria which enter via the nasopharynx. Colonization at that site may thus be an important determinant of disease (18). The finding that a specific alpha-lactalbumin derived from human as well as bovine milk inhibits attachment of both species opens  
20 the possibility to prevent colonization by specific interference of attachment using these structures. The bactericidal effect is hereby of importance as well.

The importance of the antimicrobial molecules is shown by the protection against infections which is seen in breast-fed babies. Breast-fed babies have a reduced frequency of diarrhoea, upper respiratory tract infections and acute otitis media (AOM). The bacterial species discussed in this application are the most frequent bacterial causes of AOM, viz. Haemophilus  
30 influenzae and Streptococcus pneumoniae.

As evident from the data shown the alpha-lactalbumin obtained from the human or bovine milk inhibits the attachment of S. pneumoniae and H. influenzae to human respiratory tract epithelial cells in vitro.  
35

Table 3

Bacterial adhesion to oropharyngeal cells after incubation with active human milk, casein, and casein fractions obtained after ion-exchange chromatography on DEAE-Trisacryl

5

Sample	<u>Adhesion</u>	
	<u>S. pneumoniae</u> Mean (%)	<u>H. influenzae</u> Mean (%)
Saline control	150 (100)	200 (100)
Human milk	25 (17)	70 (35)
Casein	4 (3)	10 (5)
Pool VI	14 (9)	22 (11)
Pool K	3 (2)	17 (9)
Pool L	150 (100)	178 (89)

15

Table 4

Bacterial adhesion to oropharyngeal cells after incubation with human alpha-lactalbumin and the fractions obtained after ion-exchange chromatography and gel chromatography.

20

Sample	<u>Adhesion</u>	
	<u>S. pneumoniae</u> Mean (%)	<u>H. influenzae</u> Mean (%)
Saline control	138 (100)	130 (100)
Human alpha-lactalbumin	124 (90)	110 (85)
Pool LA <sub>2</sub>	4 (3)	9 (7)
Pool LA	128 (93)	76 (58)

30

35

Table 5

Bacterial adhesion to oropharyngeal cells after incubation with bovine alpha-lactalbumin and the fractions obtained after ion-exchange chromatography and gel chromatography.

5

Sample	<u>Adhesion</u>	
	<u>S. pneumoniae</u> Mean (%)	<u>H. influenzae</u> Mean (%)
10 Saline control	138 (100)	130 (100)
Bovine alpha-lactalbumin	130 (94)	99 (76)
Pool BL <sub>2</sub>	3 (2)	18 (14)

## 15 APPLICATIONS

The alpha-lactalbumin of the present invention can be administered in the form of an oral mucosal dosage unit, an injectable composition, or a topical composition. In any case the protein is normally administered together with commonly known  
 20 carriers, fillers and/or expedients, which are pharmaceutically acceptable.

In case the protein is administered in the form of a solution for topical use the solution contains an emulsifying agent for  
 25 the protein together with an diluent which can be sprayed into the nasopharynx, or can be inhaled in the form of a mist into the upper respiratory airways.

In oral use the protein is normally administered together with  
 30 a carrier, which may be a solid, semi-solid or liquid diluent or a capsule. These pharmaceutical preparations are a further object of the present invention. Usually the amount of active compound is between 0.1 to 99 % by weight of the preparation, preferably between 0.5 to 20 % by weight in preparations for  
 35 injection and between 2 and 50 % by weight in preparations for oral administration.

In pharmaceutical preparations containing a protein of the present invention in the form of dosage units for oral administration the compound may be mixed with a solid, pulverulent carrier, as e.g. with lactose, saccharose, sorbitol, mannitol, starch, such as potatoe starch, corn starch, amylopectin, cellulose derivatives or gelatine, as well as with an antifriction agent such as magnesium stearate, calcium stearate, polyethylene glycol waxes or the like, and be pressed into tablets. Multiple-unit-dosage granules can be prepared as well. Tablets and granules of the above cores can be coated with concentrated solutions of sugar, etc. The cores can also be coated with polymers which change the dissolution rate in the gastrointestinal tract, such as anionic polymers having a  $pK_a$  of above 5.5. Such polymers are hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, and polymers sold under the trade mark Eudragit S100 and L100.

In the preparation of gelatine capsules these can be soft or hard. In the former case the active compound is mixed with an oil, and the latter case the multiple-unit-dosage granules are filled therein.

Liquid preparations for oral administration can be present in the form of syrups or suspensions, e.g., solutions containing from about 0.2 % by weight to about 20 % by weight of the active compound disclosed, and glycerol and propylene glycol. If desired, such preparations can contain colouring agents, flavouring agents, saccharine, and carboxymethyl cellulose as a thickening agent.

The daily dose of the active compound varies and is dependent on the type of administrative route, but as a general rule it is 1 to 100 mg/dose of active compound at peroral administration, and 2 to 200 mg/dose in topical administration. The number of applications per 24 hrs depend of the administration route, but may vary, e.g. in the case of a topical application in the nose from 3 to 8 times per 24 hrs, i.a., depending on

the flow of phlegm produced by the body treated in therapeutic use. In prophylactic use the number may be on the lower side of the range given.

- 5 The topical form can preferably be used in prophylactic treatment, preferably in connection with an infection caused by a rhinitis virus.

10 The protein can also be used as an additive in infant food, particularly for prophylactic reasons, in order to supply the casein in an easy way to the child. Infants normally reject pharmaceuticals for different reasons. The food product can thus be in the form of a pulverulent porridge base, gruel base, 15 milk substitute base, or more complex food product as of the Scotch collops type, comprising vegetables and meat pieces, often in disintegrated form.

In the case of protein administration to animals they are normally added to the feedstuffs, which besides the protein contains 20 commonly used nutrients.

In accordance with a further aspect of the invention there is provided a process for determining the presence of S. pneumo-  
25 cocci and H. influenzae in a sample taken from the respiratory tract of an animal or human. This process is based on the technique of determining the degree of interaction between the bacteria of the sample and a composition of the present invention. Such interaction may be determined by inhibition or induction of the adherence of the bacteria to cells or other surfaces.

30

35

## REFERENCES

1. McKenzie, H.A., White, F.H. Jr  
Adv. Protein Chem. 41:173, 1991
2. Hopper, K.E. and McKenzie, H.A.  
5 Biochim. Biophys. Acta 295:352, 1973
3. Schmidt, D.V. and Ebner, K.E.  
Biochim. Biophys. Acta 263:714, 1972
4. Maynard, F.  
J. Dairy Res. 59:425, 1992
- 10 5. Barman, T.E.  
Eur. J. Biochim. 37:86, 1973
6. Readhead, K., Hill, T. and Mulloy, B.  
FEMS Microbiol Lett. 70:269, 1990
7. Gilin, F.D., Reiner, D.S. and Wang, C.S.  
15 Science 221:1290, 1983
8. Fiat, A.-M., and Jolles, P.  
Mol. Cell Biochem. 87:5, 1989
9. Matthews, T.H.J., Nair, C.D.G., Lawrence, M.K. and Tyrrell,  
D.A.J.  
20 Lancet, December, 25:1387, 1976
10. Andersson, B., Dahmén, J., Frejd, T., Leffler, H.,  
Magnusson, G., Noori, G., and Svanborg, C.,  
J. Exp. Med., 158:559, 1983
11. Svanborg, C., Aniansson, G., Mestecky, J., Sabharwal, H.,  
25 and Wold, A.  
In Immunology of milk and the neonate, J. Mestecky ed.  
Plenum Press, New York, 1991
12. Svanborg-Edén, C. and Svennerholm, A.-M.,  
Infect. Immun. 22:790, 1978
- 30 13. In Microbial lectins and agglutinins, properties and bio-  
logical activity, Mirelman, D., Wiley, New York, 1986
14. Andersson, B., Porras, O., Hansson, L.Å., Lagergård, T. and  
Svanborg-Edén, C.  
J. Infect. Dis. 153:232, 1986
- 35 15. Aniansson, G., Andersson, B., Lindstedt, R., and Svanborg,  
C.,  
Microbial Pathogenesis 8, 365, 1990



16. Sabharwal, H., Hansson, C., Nilsson, A.K., Saraf, A.,  
Lönnerdahl, B., and Svanborg, C.  
1993, submitted
17. Lacks, S., and Hotchiss, R.D.  
5 Biochim. Biophys. Acta, 38:508, 1960
18. Branefors-Helander, P.  
Acta Pathol. Microbiol. Immunol. Scand. (B), 80:211, 1972
19. Porras, O., Svanborg Edén, C., Lagergård, T., and Hansson,  
L. Å.  
10 Eur. J. Clin. Microbiol., 4, 310-15, 1985
20. Vanaman, T.C., Brew, K., and Hill, R.L.  
J. Biol. Chem. 245:4583, 1970
21. Beachey, E.H.,  
J. Infect. Dis. 143, 325, 1981
- 15 22. Andersson, B., Beachey, E.H., Tomasz, A., Tuomanen, E., and  
Svanborg, C.,  
Microbial Pathogenesis, 4, 267, 1988
23. Andersson, B., Eriksson, B., Falsén, E., et al  
Infect. Immun. 32, 311-17, 1981

20

25

30

35

CLAIMS

1. The use of a multimeric alpha-lactalbumin in the preparation of therapeutically and/or prophylactically active antibacterial preparations, against infections, preferably of the respiratory tract, caused by bacteria, in particular S. pneumoniae and/or H. influenzae.
2. Use according to claim 1, wherein the multimeric alpha-lactalbumin is present in a mixture of monomeric, dimeric and trimeric forms.
3. Use according to claim 2, wherein the monomeric, dimeric, and trimeric forms are present in a weight ratio of about 15-7:5-2:1
4. Use according to claim 3, wherein the monomeric, dimeric, and trimeric forms are present in a weight ratio of about 10:3:1
5. Pharmaceutical composition comprising a therapeutically active amount of a protein as defined in any of claims 1-4 for the therapeutic and/or prophylactic treatment of infections, preferably in the respiratory tract, caused by bacteria, in particular S. pneumoniae and/or H. influenzae.
6. Food and feed-stuff comprising an active amount of a protein as defined in any of claims 1-4 for the therapeutic and/or prophylactic treatment of infections, preferably in the respiratory tract, caused by bacteria, in particular S. pneumoniae and/or H. influenzae.
7. Method for prophylactic and/or therapeutic treatment of infections caused by bacteria, in particular S. pneumoniae and/or H. influenzae, wherein a therapeutically active amount of a protein as defined in any of claims 1-4 is administered to mammals, including humans, optionally in combination with therapeutically inert expedients or nutrients.

8. Method according to claim 7, wherein the alpha-lactalbumin is administered to prevent adhesion of virulent bacteria.

5 9. Method according to claim 7, wherein the alpha-lactalbumin is administered to exert a bactericidal effect on the virulent bacteria.

10 10. Method according to claim 7, wherein the alpha-lactalbumin is administered to provide a bactericidal effect on a virulent bacteria.

11. Method for diagnosing infections caused by bacteria, in particular S. pneumoniae and/or H. influenzae, wherein a sample from the infected mammals, including man is extracted and determined with regard to adhesion visavi a protein as defined in any of claims 1-4.

12. Method for preparing a protein according to any of claims 1-4, wherein a monomeric alpha-lactalbumin is subjected to an ion-exchange chromatography.

13. Method according to claim 12, wherein the ion-exchange chromatography is carried out on a DEAE-Tris-acryl gel.



25 14. Method according to claim 13, wherein the eluting agent is NaCl having a linear gradient.

15. Method for preparing a therapeutically and/or prophylactically active antibacterial preparation against infections caused, preferably in the respiratory tract by S. pneumoniae and/or H. influenzae, whereby a therapeutically active amount of multimeric alpha-lactalbumin is combined with inert ex-

35

1/4



FIG 1



SUBSTITUTE SHEET


2 / 4

FIG 2

**SUBSTITUTE SHEET**

3/4

FIG 3



4 / 4




FIG 4

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00742

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/38, A61K 35/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, WPI, WPIL, PAJ, US PATENTS FULLTEXT DATABASES

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A1, 0339656 (GOLD, PHIL), 2 November 1989 (02.11.89), page 2, line 35 - line 36; page 7, line 40 - line 50, see the claims; the abstract  --	1-6,11,15
X	Dialog Information Service, file 5, Biosis Dialog accession No. 4510781, Biosis accessiion No. 7888460, Herlea V et al: "Testing the Anti Microbial Activity of some Active Factors Isolated from Human Milk and Colostrum", REV Roum Biol Ser Biol Veg 28 (2). 1983 (REOD, 1984), 145-152  --	1-6,11,15

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

31 March 1995

Date of mailing of the international search report

05 -04- 1995

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Palmcrantz

Telephone No. +46 8 782 25 00



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00742

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5290571 (GUSTAVO BOUNOUS ET AL), 1 March 1994 (01.03.94), column 5, line 11; column 19, line 33 - column 20, line 25, the claims  --	1-6,11,15
X	EP, A1, 0022696 (INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)), 21 January 1981 (21.01.81)  --	5-6
X	Biochim.Biophys.Acta, Volume 229, 1971, Nancy I. Phillips et al, "Isolation and Properties of Human alfa-Lactalbumin" page 408, line 15 - line 18  --	12-14
X	FR, A1, 2671697 (SNOW BRAND MILK PRODUCTS CO.LTD.), 24 July 1992 (24.07.92), see the claims  -- -----	12-14

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 94/00742

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7-10  
because they relate to subject matter not required to be searched by this Authority, namely:  
See PCT Rule 39.1 (iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

25/02/95

International application No.

PCT/SE 94/00742

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0339656	02/11/89	SE-T3- 0339656	
		AT-T- 113474	15/11/94
		CA-A- 1333471	13/12/94
		DE-D- 68919114	00/00/00
		ES-T- 2065352	16/02/95
		JP-A- 2152929	12/06/90
		US-A- 5230902	27/07/93
		US-A- 5290571	01/03/94
		AU-B- 638439	01/07/93
		AU-A- 4670189	28/06/90
		CA-A- 2005779	23/06/90
		CN-A- 1044659	15/08/90
		EP-A- 0374390	27/06/90
		EP-A- 0375852	04/07/90
		JP-A- 3139245	13/06/91
		NZ-A- 231865	25/02/94
US-A- 5290571	01/03/94	AT-T- 113474	15/11/94
		CA-A- 1333471	13/12/94
		DE-D- 68919114	00/00/00
		EP-A, A, A 0339656	02/11/89
		SE-T3- 0339656	
		ES-T- 2065352	16/02/95
		JP-A- 2152929	12/06/90
		US-A- 5230902	27/07/93
		AU-B- 638439	01/07/93
		AU-A- 4670189	28/06/90
		CA-A- 2005779	23/06/90
		CN-A- 1044659	15/08/90
		EP-A- 0374390	27/06/90
		EP-A- 0375852	04/07/90
		JP-A- 3139245	13/06/91
		NZ-A- 231865	25/02/94
EP-A1- 0022696	21/01/81	SE-T3- 0022696	
		AU-B- 538288	09/08/84
		AU-A- 5966680	08/01/81
		CA-A- 1136919	07/12/82
		FR-A, B- 2459619	16/01/81
		JP-C- 1701735	14/10/92
		JP-B- 3062720	26/09/91
		JP-A- 56036494	09/04/81
		US-A- 4485040	27/11/84
		US-A- 4711953	08/12/87
FR-A1- 2671697	24/07/92	JP-A- 4330252	18/11/92